CONNECT BIOPHARMA HOLDINGS L (CNTB)

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in San Diego, California and currently employs 100 full-time employees. The company went IPO on 2021-03-19. The firm is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). The company has clinical development activities in the United States, the People’s Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.

Company Info

CONNECT BIOPHARMA HOLDINGS L

12265 El Camino Real, Suite 350

San Diego CALIFORNIA 215400

P: 18587271040

CEO: William Pan

Employees: 100

Website: https://www.connectbiopharm.com